



---

---

**SYNTHESIS, CHARACTERIZATION AND ANTIMICROBIAL ANALYSIS OF VARIOUS SUBSTITUTED 2-(5-(3-(5-BROMOTHIOPHEN-2-YL)-1-PHENYL-1H-PYRAZOL-4-YL)-1H-PYRAZOL-3-YL) PHENOLS**

**Sunil S. Bhagat<sup>a\*</sup>, Amol J. Shirsat<sup>a</sup>, Balaji D. Rupnar<sup>a</sup>, Charansingh H. Gill<sup>b</sup>**

<sup>a</sup>*Department of Chemistry, R. B. Attal Arts, Science and Commerce College, Georai, Dist- Beed-431127, Maharashtra, India*

<sup>b</sup>*Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad-431004, Maharashtra, India*

*[E-mail-sunilbhagat2010@gmail.com](mailto:E-mail-sunilbhagat2010@gmail.com)*

---

**Abstract:** The title compounds various substituted 2-(5-(3-(5-bromothiophen-2-yl)-1-phenyl-1H-pyrazol-4-yl)-1H-pyrazol-3-yl) phenols **2(a-h)** have been synthesized from chromones **1(a-h)** by refluxing with potassium hydroxide. The structures of all newly synthesized compounds have been confirmed by IR, <sup>1</sup>H NMR and Mass spectral data. The synthesized compounds have been screened for their antimicrobial activity. Some of the compounds show moderate antimicrobial activity as compared to the reference drugs Ciprofloxacin and Fluconazole.

**Keywords:** Chromones, Antimicrobial activity


---

### Introduction

Pyrazole is characterized by a 5-membered heterocyclic ring structure made up of three carbon atoms and two nitrogen atoms in adjacent positions. 1-pyrazolyl-alanine, the first natural pyrazole, was obtained from watermelon seeds in 1959. It has pharmacological effects on humans, they are rare in nature. They have application in pharmaceutical industry and agrochemicals as active pharmaceuticals and herbicides. The current achievement of pyrazole COX-2 inhibitor has more emphasized the prominence of these heterocyclic rings in medicinal chemistry. A logical examination of this class of heterocyclic lead has shown that pyrazole containing pharmacoactive

agents play vital role in medicinal chemistry. The occurrence of pyrazole nuclei in naturally active molecules has encouraged the need for well-designed and effective methods to make these heterocyclic lead [1].

Nitrogen-linked heterocyclic compounds gained substantial consideration in modern times because of their pesticidal and medicinal significance [2-4]. Pyrazole derivatives are important in pesticide industry and extensively used because of their antiviral[5], antitumor[6], anti-inflammatory[7], antibacterial[8], herbicidal[9], insecticidal[10], fungicidal activities[11], Angiotensin-I-converting enzymes inhibitory[12], molluscicidal [13], and ulcerogenic activity[14].



Scheme 1

## Experimental Section

**General Procedure for the synthesis of 2-(5-(3-(5-bromothiophen-2-yl)-1-phenyl-1H-pyrazol-4-yl)-1H-pyrazol-3-yl)-4-methylphenol (2b):** Compound **1b** (0.003 mol) was taken in 100 ml RBF with 15 ml ethanol. To this reaction mixture 1 ml hydrazine hydrate and 0.5 gm KOH were added and the contents were heated under reflux for five hour. After completion of reaction (monitored

by TLC), the contents were cooled to room temperature and poured over crushed ice and acidified with HCl. The solid thus obtained was separated by filtration and crystallized from ethanol. The compounds **2 (a-h)** were prepared by following the above procedure. The physical data of the compounds **2 (a-h)** were recorded in **Table 1**. Their structures have been confirmed by <sup>1</sup>HNMR, Mass and IR spectra.

**Table 1:** Physical data of compounds 2(a-h)

Comp.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	M.P. (°C)	Yield (%)
<b>2a</b>	H	H	H	168-170	78
<b>2b</b>	H	H	CH <sub>3</sub>	184-186	65
<b>2c</b>	H	H	Cl	136-138	78
<b>2d</b>	Cl	H	Cl	248-250	71
<b>2e</b>	H	H	F	168-170	68
<b>2f</b>	H	CH <sub>3</sub>	Cl	238-240	72
<b>2g</b>	H	H	Br	230-232	66
<b>2h</b>	CH <sub>3</sub>	H	CH <sub>3</sub>	208-210	70

**Selected spectral data of some representative compounds**  
**2-(5-(3-(5-bromothiophen-2-yl)-1-phenyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazol-3-yl)-4-chloro-5-**

**methylphenol (2b):**IR (cm<sup>-1</sup>):1054(Ar-Br), 1264(C-O),1534(C=N),1650(Ar C=C), 2835(Ar-CH<sub>3</sub>),3263(N-H),3438(O-H).<sup>1</sup>H NMR(DMSO)δ ppm: 2.300 (s, 3H, CH<sub>3</sub>), 6.8251(s,1H,Ar-



H)H), 6.8510 (s, 1H, Ar-H), 6.9621-6.9819(m, 1H, Ar-H), 7.0534-7.1103 (m, 1H, Ar-H), 7.3255-7.4335(m, 4H, Ar-H), 7.4952-7.5143(d, 1H, Ar-H,  $J=7.64$  Hz), 7.5143-7.5333(d, 1H, Ar-H,  $J=7.6$  Hz), 7.8733-7.8442(dd, 1H, Ar-H,  $J=4.48$  & 4.12 Hz), 7.9745(s, 1H, Ar-H), 8.6148(s, 1H, Pyrazole-H), 10.7410 (s, 1H, N-H), 13.3261 (s, 1H, Ar-OH). **ES-MS** (m/z): 475(M-1), 477(M+2).

### Results and Discussion

The pyrazole derivatives were synthesized successfully in moderate to good yields. The newly synthesized compounds were identified on the basis of melting point range, IR,  $^1\text{H}$  NMR, Mass spectral analysis. All the newly synthesized derivatives were screened for antimicrobial activity using disc diffusion method.

**Antimicrobial activity:** Compounds **2(a-h)** were screened for their in vitro antimicrobial activity against *Escherichia coli* (ATCC 25922), *Pseudomonas aeruginosa* (ATCC 27853), *Staphylococcus aureus* (ATCC 25923), *Staphylococcus albus*, *Klebsiella pneumoniae* using Ciprofloxacin as a reference standard drug by paper disc diffusion method. Antifungal activity was evaluated against *Candida sp.* using Fluconazole as standard drug. All the tests were evaluated at 100  $\mu\text{g/ml}$  concentration. The culture media was Muller Hinton agar. The zone of inhibition was measured in mm after 24 hr of incubation at 37°C. DMSO is used as control.

Microbial data for corresponding compounds is summarized in **Table 2**.

**Table 2** In-vitro antimicrobial activity of various substituted 2-(5-(3-(5-bromothiophen-2-yl)-1-phenyl-1H-pyrazol-4-yl)-1H-pyrazol-3-yl) phenols **2(a-h)**.

Sr. No.	Compound No.	Inhibition Zone Diameter (mm)					
		<i>Candida sp.</i>	<i>S. aureus</i>	<i>S. albus</i>	<i>Klebsiella pneumoniae</i>	<i>E. coli</i>	<i>Pseudo monas sp.</i>
1.	2a	3.9	3.9	-	-	-	5
2.	2b	4	8	6	-	8	3
3.	2c	7	9	12	10.8	9	-
4.	2d	6	4	7	10.2	5	4
5.	2e	9	-	10	1.9	13	12
6.	2f	7	-	7	2	11	10
7.	2g	8	-	9	5	6	8
8.	2h	4	-	6	5	5	7
9.	Control	8	3	3	4	6	10
10.	Ciprofloxacin	---	20	22	22	21	23
11.	Fluconazole	23	---	---	---	---	---



### Acknowledgements

The authors are thankful to The Head, Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad for providing laboratory facilities and Uday Khedkar,

Director, BAC-TEST Laboratory, Nashik for antimicrobial analysis. One of the authors (SSB) is thankful to Principal Dr. R. V. Shikhare for constant encouragement.

### References

- [1] Eicher, T.; Hauptmann, S. The Chemistry of Heterocycles: Structure, Reactions, Syntheses, and Applications, Edition II, 2003, Wiley-VCH, ISBN 3527307206.
- [2] Liu, X.H.; Chen, P.Q.; Wang, B.L.; Li, Y.H.; Wang, S.H.; Li, Z.M. *Bioorg. Med. Chem. Lett.* (2007), 17, 3784.
- [3] Liu, X.H.; Zhang, C.Y.; Guo, W.C.; Li, Y.H.; Chen, P.Q.; Wang, T.; Dong, W.L.; Sun, H.W.; Li, Z.M. *J. Enzym. Inhib. Med. Chem.* (2009), 73, 320.
- [4] Liu, X.H.; Shi, Y.X.; Ma, Y.; Zhang, C.Y.; Dong, W.L.; Li, P.; Wang, B.L.; Li, B.J.; Li, Z.M. *Eur. J. Med. Chem.* (2009), 44, 2782.
- [5] (a) Sayed, H.H.; Ali, M.A. *Phosphorus Sulfur Silicon Relat Elem.* (2008), 183, 156; (b) Rashad, A. E.; Hegab, M. I.; Abdel-Megeid, R. E.; Micky, J. A.; Abdel-Megeid, F. M. E. *Bioorg. Med. Chem.* (2008), 16, 7102 ; (c) Park, H.J.; Lee, K.; Park, S.J.; Ahn, B.; Lee, J.C.; Cho, H.; Lee, K.I. *Bioorg Med Chem Lett.* (2005), 15, 3307 ; (d) Peng-Cheng, L.; Zhu, H.; Li, H.; Sun, J.; Zhou, Y. *Bioorg. Med. Chem.* (2010), 18, 4606 ; (e) Barnes, B. J.; Izydore, R. A.; Hall, I. H. *Anticancer Res.*, (2001), 21(4A), 2313; (f) Baraldi, P. G.; Balboni, G.; Pavani, M. G.; Spalluto, G.; Tabrizi, M. A.; Clercq, E. D. *J. Med. Chem.* (2001), 44(16), 2536.
- [6] Baraldi, P. G.; Pavani, M. G.; Nunez, M. C.; Brigidi, P.; Vitali, B.; Gambari, R., *Bioorg. Med. Chem.*, (2002), 10(2), 449.
- [7] Burguete, A.; Pontiki, E.; Hadjipavlou-Litina, D.; Villar, R.; Vicente, E.; Solano, B.; Ancizu, S.; Perez-Silanes, S.; Aldana, I.; Monge, A. *Bioorg Med Chem Lett.* (2007), 17, 6439.
- [8] (a) Farghaly, A.A.; Vanelle, P.; El-Kashef, H.S. *Heterocycl Comm.* (2005), 11, 255 ; (b) Sridhar, R.; Perumal, P. J.; Etti, S.; Shanmugam, G.; Ponnuswamy, M. N.; Prabavathy, V. R.; Mathivanan, N. *Bioorg. Med. Chem. Lett.* (2004), 14, 6035.
- [9] He, F.Q.; Liu, X.H.; Wang, B.L.; Li, Z.M. *Heteroatom Chem.* (2008), 19, 21.
- [10] Jiang, L.; Wang, L.Z.; Wang, L.Y.; Xie, X.Y. *Hecheng Huaxue.* (2007), 15, 576.
- [11] Yang, X.D.; Yu, Y.Y. *Struct Chem.* (2008), 19, 693. [12] Bonesi, M.; Loizzo, M. R.; Statti, G. A.; Michel, S.; Tillequin, F.; Menichini. *Bioorg. Med. Chem. Lett.* (2010), 20, 1990.
- [13] Nawwar, G. A.; Swellem, R. H.; Ibrahim, A. M. *Arch. Pharm.*, (1994), 17(2), 66.
- [14] Ochi, T.; Sugiyama, A. Y.; Ohkubo, Y.; Sakane, K.; Tanaka, H. J. *Pharmacol.* (2001), 85(2), 175.